<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Mantle cell lymphoma: Initial management</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Mantle cell lymphoma: Initial management</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Mantle cell lymphoma: Initial management</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Arnold S Freedman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan W Friedberg, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alex F Herrera, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew Lister, MD, FRCP, FRCPath, FRCR</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ann S LaCasce, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alan G Rosmarin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 31, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Mantle cell lymphoma (MCL) is B cell non-Hodgkin lymphoma (NHL) with features of both indolent and aggressive NHLs that has a heterogeneous natural history. MCL is usually composed of small- to medium-sized lymphoid cells that express BCL2, CD5, and nuclear cyclin D1. Nearly all cases have the t(11;14) chromosomal translocation, which involves rearrangement of an immunoglobulin heavy chain and <em>CCND1</em> (the gene that encodes cyclin D1), resulting in overexpression of cyclin D1.</p><p>Most cases of MCL (ie, "classic" or "aggressive" MCL) present with multiple sites of lymph node involvement, with or without extranodal involvement, and have an aggressive natural history. However, one-fifth of patients manifest a more indolent course that may not require immediate treatment. Conversely, patients with certain adverse clinical or pathologic features respond poorly to conventional therapy. Rare patients manifest limited-stage (stage I) MCL. Patients with indolent MCL, adverse features, or stage I MCL often require distinctive management.</p><p>Initial treatment of MCL is discussed in this topic. </p><p>Related topics include:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4702.html" rel="external">"Mantle cell lymphoma: Epidemiology, pathobiology, clinical manifestations, diagnosis, and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/4735.html" rel="external">"Treatment of relapsed or refractory mantle cell lymphoma"</a>.)</p><p></p><p class="headingAnchor" id="H3"><span class="h1">PRETREATMENT EVALUATION</span><span class="headingEndMark"> — </span>Pretreatment evaluation of a patient with mantle cell lymphoma (MCL) includes disease staging and assessment of comorbid conditions that can affect treatment, including suitability for autologous transplantation.</p><p class="headingAnchor" id="H3775108263"><span class="h2">Clinical and laboratory</span><span class="headingEndMark"> — </span>History and physical examination, laboratory and clinical testing, and imaging are used to determine disease stage. MCL is staged according to Lugano criteria  (<a class="graphic graphic_table graphicRef97479" href="/z/d/graphic/97479.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]. </p><p>We perform the following pretreatment studies in patients with MCL:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical</strong> – History and physical examination should evaluate the patient for constitutional "B" symptoms (ie, fevers, sweats, unintentional weight loss). Special attention should be given to gastrointestinal symptoms, enlargement of liver and spleen, and possible involvement of Waldeyer's ring.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory</strong> <strong>studies</strong> – Screening laboratory studies should include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hematology</strong> – Complete blood count (CBC) and differential count.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Chemistries</strong> – Electrolytes, glucose, kidney function, liver function tests, lactate dehydrogenase (LDH), and uric acid.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Infections</strong> – HIV and Hepatitis B testing (including hepatitis B surface antigen and core antibody). For patients with a history of hepatitis B, e antigen and viral load should be measured and consultation with a gastroenterologist or hepatologist is helpful.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging</strong> – Positron emission tomography (PET)/computed tomography (CT) or contrast-enhanced CT of chest, abdomen, and pelvis. PET activity is judged according to the five-point PET scale (Deauville score)  (<a class="graphic graphic_table graphicRef108973" href="/z/d/graphic/108973.html" rel="external">table 2</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical testing</strong> – The following tests are performed in selected patients:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Cardiac</strong> – Echocardiogram or radionuclide ventriculogram (RVG or MUGA) should be performed if treatment with an anthracycline is expected.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Gastroenterology</strong> – We generally obtain upper endoscopy and colonoscopy only for patients with gastrointestinal (GI) symptoms. </p><p></p><p class="bulletIndent2">Some experts perform these studies to exclude subclinical GI involvement for patients who appear to have stage I disease based on clinical evaluation and imaging.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Bone marrow examination</strong> – Bone marrow examination should be performed to evaluate unexplained cytopenias and to confirm stage I disease; it is not required for staging other patients with MCL. </p><p></p><p class="bulletIndent2">We perform bone marrow examination for patients who appear to have stage I disease based on clinical evaluation and imaging. Bone marrow examination is generally not required if MCL cells are seen on the blood smear or if there is obvious marrow involvement on PET; note that PET is not sensitive for marrow involvement by MCL.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Neurologic</strong> – Patients with unexplained neurologic findings should undergo central nervous system (CNS) imaging and lumbar puncture (LP), including cytology and flow cytometry of cerebrospinal fluid. </p><p></p><p class="bulletIndent2">If an LP is planned and there are concerns about seeding the CNS with circulating MCL cells, the diagnostic procedure can be combined with administration of intrathecal chemotherapy, or the LP can be deferred until the white blood cell count has declined after beginning systemic therapy.</p><p></p><p class="bulletIndent2">Some experts perform an LP for all patients who have the blastoid variant of MCL, regardless of neurologic abnormalities, because of an increased risk of CNS involvement [<a href="#rid2">2</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fertility counseling</strong> – Patients of childbearing potential should receive counseling about the potential effect of treatment on their fertility and options for fertility-preserving measures. (See  <a class="medical medical_review" href="/z/d/html/7440.html" rel="external">"Fertility and reproductive hormone preservation: Overview of care prior to gonadotoxic therapy or surgery"</a>.)</p><p></p><p>General approaches to the diagnostic work-up and staging of non-Hodgkin lymphoma are presented separately  (<a class="graphic graphic_table graphicRef97479" href="/z/d/graphic/97479.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/4695.html" rel="external">"Clinical presentation and initial evaluation of non-Hodgkin lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/4696.html" rel="external">"Pretreatment evaluation and staging of non-Hodgkin lymphomas"</a>.)</p><p class="headingAnchor" id="H3339173436"><span class="h2">MCL subtypes</span><span class="headingEndMark"> — </span>There are two major subtypes of MCL that are distinguished by clinical presentation and pathologic features [<a href="#rid3">3,4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classic (aggressive) MCL</strong> – Most cases of MCL have an aggressive course, whether it manifests as nodal disease, extranodal involvement (eg, GI tract or marrow), or both. </p><p></p><p class="bulletIndent1">The malignant cells of classic MCL have unmutat<em>ed IGHV</em> genes, overexpress SOX11, and often have other mutations and epigenetic modifications. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indolent MCL</strong> – Approximately 20 percent of cases of MCL have an indolent course with a more favorable prognosis [<a href="#rid5">5</a>]. The malignant cells generally have mutated<em> IGHV</em>, a low proliferative fraction (eg, Ki-67 &lt;10 percent), and do not express SOX11 [<a href="#rid6">6</a>]. Common presentations of indolent MCL include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Leukemic, non-nodal MCL</strong> – Leukemic, non-nodal MCL typically presents with lymphocytosis and splenomegaly that resembles chronic lymphocytic leukemia, but it may become aggressive if mutations of <em>TP53</em> or other key genes are acquired. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>GI tract-only involvement</strong> – For patients with MCL that involves the GI tract-only (especially when it is limited to microscopic disease), the natural history is generally indolent. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Indolent nodal MCL</strong> – A subset of patients with nodal MCL have indolent disease. Such cases usually manifest low disease burden, normal serum lactate dehydrogenase (LDH), and low Ki-67 index.</p><p></p><p class="bulletIndent1">Management of indolent MCL is discussed below. (See <a class="local">'Indolent MCL'</a> below.)</p><p></p><p class="headingAnchor" id="H592360254"><span class="h2">Disease stage</span><span class="headingEndMark"> — </span>We distinguish management of MCL according to disease stage, as follows: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Advanced-stage MCL</strong> – Nearly all patients with MCL present with advanced-stage disease (stages II to IV MCL and any case with &gt;10 cm disease ["bulky" disease]).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Limited-stage (ie, stage I) MCL</strong> – True stage I MCL (ie, non-bulky disease involving only a single lymph node region) is extremely rare. </p><p></p><p class="bulletIndent1">Nearly all cases of suspected stage I MCL are found to have other sites of subclinical involvement, such as disease of the GI tract or marrow involvement. We generally perform endoscopy/colonoscopy and bone marrow examination in patients who appear to have stage I disease based on clinical evaluation and imaging. (See <a class="local">'Clinical and laboratory'</a> above.)</p><p></p><p class="bulletIndent1">Management of limited-stage MCL is discussed below. (See <a class="local">'Stage I MCL'</a> below.) </p><p></p><p class="headingAnchor" id="H635605718"><span class="h2">Fitness</span><span class="headingEndMark"> — </span>We assess functional (performance) status and determine if the patient is a candidate for intensive therapies, including autologous transplantation. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Performance status</strong> – We assess functional status according to ECOG or Karnofsky score  (<a class="graphic graphic_table graphicRef57945" href="/z/d/graphic/57945.html" rel="external">table 3</a>).  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Transplant eligibility</strong> – Autologous hematopoietic cell transplantation (HCT) is a standard approach for consolidation therapy with MCL. Soon after diagnosing MCL, we refer fit individuals ≤65 years to transplant specialists to evaluate eligibility for autologous HCT, which requires adequate performance status and good kidney, liver, heart, and lung function, as discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16354.html" rel="external">"Determining eligibility for autologous hematopoietic cell transplantation"</a>.)</p><p></p><p class="headingAnchor" id="H3918803297"><span class="h2">Prognostic factors</span><span class="headingEndMark"> — </span>We evaluate patients using a clinical prognostic index and assess pathologic features of the tumor cells prior to treatment. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognostic index</strong> – The Mantle Cell Lymphoma International Prognostic Index (MIPI) (<a class="calc calc_professional" href="/z/d/html/83044.html" rel="external">calculator 1</a>)  (<a class="graphic graphic_table graphicRef86535" href="/z/d/graphic/86535.html" rel="external">table 4</a>) can be used to stratify patients with MCL into low-, intermediate-, and high-risk groups [<a href="#rid7">7</a>]. </p><p></p><p class="bulletIndent1">Modified versions incorporate Ki-67 index (MIPI-B) or <em>miR-18b</em> (MIPI-B-miR) into the MIPI model; these modified indices were effective for estimating prognosis in trials with long-term follow-up [<a href="#rid8">8-10</a>]. MIPI was more accurate than the International Prognostic Index (IPI) for predicting survival outcomes in an analysis of 158 patients receiving intensive induction chemoimmunotherapy and autologous HCT [<a href="#rid11">11</a>]. </p><p></p><p class="bulletIndent1">MIPI is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/4702.html" rel="external">"Mantle cell lymphoma: Epidemiology, pathobiology, clinical manifestations, diagnosis, and prognosis", section on 'Prognostic features'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathologic features</strong> – We consider pathologic features of the tumor cells when planning management.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Adverse </strong>– The following features are associated with especially poor outcomes in patients with advanced-stage MCL and may influence management (see <a class="local">'MCL with adverse features'</a> below):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Mutated</strong> <strong><em>TP53</em></strong> </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Blastoid phenotype </strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Complex karyotype</strong> – ≥3 chromosomal abnormalities, in addition to t(11;14) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Favorable </strong>– Up to one-fifth of cases of MCL are SOX11-negative; many such cases manifest as leukemic, non-nodal MCL (eg, blood, marrow, and/or spleen) or GI tract-only disease, while sparing lymph nodes. (See <a class="local">'Indolent MCL'</a> below.) </p><p></p><p class="headingAnchor" id="H2565285447"><span class="h1">OVERVIEW OF MANAGEMENT</span><span class="headingEndMark"> — </span>Most patients with MCL present with symptomatic disease that requires treatment, but selected patients may benefit from initial observation. (See <a class="local">'Indolent MCL'</a> below.)</p><p>For patients with MCL who receive systemic therapy, we recommend treatment that includes <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> plus chemotherapy, rather than chemotherapy alone, based on improved survival and little toxicity.   </p><p>A meta-analysis of seven studies (which included 1943 patients with MCL or indolent lymphomas) reported that, compared with chemotherapy alone, treatment that included <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> was associated with superior OS, response rates, and disease control [<a href="#rid12">12,13</a>]. Mortality benefits were seen in the subset of patients with MCL (HR 0.60, 95% CI 0.37-0.98). Observational data also support a survival benefit with the addition of rituximab to chemotherapy (median survival 37 months versus 27 months) [<a href="#rid14">14</a>]. </p><p>Management of MCL is guided by the clinical presentation and pathologic features of the disease. </p><p>The natural history of MCL is heterogeneous; while most patients have classic (aggressive) MCL, a minority of patients have indolent MCL, which may be observed rather than treated at diagnosis. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classic (aggressive) MCL</strong> – Most patients present with advanced-stage nodal MCL (stages II-IV and all cases with disease &gt;10cm), with or without extranodal involvement of the gastrointestinal (GI) tract, bone marrow, blood, or other sites. </p><p></p><p class="bulletIndent1">Management of classic MCL is stratified according to age and fitness. (See <a class="local">'Fit, younger patients'</a> below and <a class="local">'Older or less-fit patients'</a> below.)</p><p></p><p class="bulletIndent1">Treatment comprises  (<a class="graphic graphic_algorithm graphicRef141184" href="/z/d/graphic/141184.html" rel="external">algorithm 1</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Induction therapy</strong> – Induction chemoimmunotherapy seeks to relieve symptoms and reduce disease burden in anticipation of post-induction management. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Post-induction therapy</strong> – Induction therapy, alone, is rarely sufficient to achieve long-term disease control of MCL. Post-induction therapy for nodal MCL is used to sustain symptom relief and prolong survival. </p><p></p><p class="bulletIndent2">Post-induction therapy is guided by medical fitness and comprises:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Consolidation therapy</strong> – For younger (eg, ≤60 or ≤65 years), medically-fit patients, autologous hematopoietic cell transplantation (HCT) is considered a standard approach for consolidation therapy. Routine use of autologous HCT may evolve with changes in induction therapy, as discussed below. (See <a class="local">'Fit, younger patients'</a> below.)  </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Maintenance therapy</strong> – Maintenance therapy refers to prolonged, lower intensity treatment following autologous HCT or after completing induction chemoimmunotherapy. (See <a class="local">'Post-transplant maintenance therapy'</a> below and <a class="local">'Maintenance therapy'</a> below.)</p><p></p><p class="bulletIndent1">Nodal MCL with mutated <em>TP53</em>, the blastoid variant, or central nervous system involvement is often poorly controlled using standard treatments. We strongly encourage such patients to participate in a clinical trial, when available. Management of MCL with adverse features is discussed below. (See <a class="local">'MCL with adverse features'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indolent MCL </strong>– Approximately one-fifth of patients with MCL have a more indolent natural history. </p><p></p><p class="bulletIndent1">Many indolent cases manifest as leukemic, non-nodal MCL (which typically presents asymptomatically with splenomegaly and/or blood and marrow involvement) or GI tract-only disease. However, some cases of nodal MCL, especially those with low tumor burden nodal involvement, normal serum lactate dehydrogenase (LDH), and low Ki-67 index may have an indolent course. Management of indolent forms of MCL is discussed below. (See <a class="local">'Indolent MCL'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Limited-stage MCL </strong>– Presentation with asymptomatic stage I MCL (ie, non-bulky disease involving a single lymph node region) is extremely rare. In nearly all cases, thorough evaluation reveals subclinical involvement of the GI tract or other sites. Management of stage I MCL is discussed below. (See <a class="local">'Stage I MCL'</a> below.)</p><p></p><p>MCL occasionally presents with intestinal obstruction or intussusception caused by extensive intestinal polyposis. Surgery may be of value for patients who present with bowel obstruction or uncontrollable bleeding from intestinal polyposis. (See  <a class="medical medical_review" href="/z/d/html/4743.html" rel="external">"Clinical presentation and diagnosis of primary gastrointestinal lymphomas"</a>.)</p><p>Management of MCL is evolving as newer agents and regimens are incorporated into standard care. Our approach is consistent with various national and international guidelines and expert panels, including the National Comprehensive Cancer Network, American Society of Transplantation and Cellular Therapy, Center for International Blood and Marrow Transplant Research, European Society for Blood and Marrow Transplantation, European Society for Medical Oncology, and European Hematology Association [<a href="#rid15">15-18</a>].</p><p class="headingAnchor" id="H2437470782"><span class="h1">FIT, YOUNGER PATIENTS</span><span class="headingEndMark"> — </span>We judge fitness and age in this setting according to suitability for intensive therapies, including autologous hematopoietic cell transplantation (HCT).</p><p>Eligibility for autologous HCT varies among institutions, but generally requires age ≤60 or ≤65 years and adequate heart, lung, liver, and kidney function, as described separately. (See  <a class="medical medical_review" href="/z/d/html/16354.html" rel="external">"Determining eligibility for autologous hematopoietic cell transplantation"</a>.)</p><p class="headingAnchor" id="H2575696740"><span class="h2">Induction therapy for fit, younger patients</span><span class="headingEndMark"> — </span>For medically-fit, younger patients with classic MCL, we suggest induction therapy using <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> plus <a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">bendamustine</a> (R-B) or one of the high-dose <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">cytarabine</a> (HiDAc)-containing intensive regimens listed below  (<a class="graphic graphic_algorithm graphicRef141184" href="/z/d/graphic/141184.html" rel="external">algorithm 1</a>), rather than R-CHOP (rituximab, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>) or R-HyperCVAD (rituximab, hyperfractionated cyclophosphamide, vincristine, <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>, alternating with high-dose <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> and cytarabine). This suggestion is based on the favorable balance of toxicity and long-term survival using the preferred induction regimens for patients who will proceed to autologous HCT as consolidation therapy. </p><p>Note that selected patients with indolent MCL can be initially observed, rather than immediately initiating therapy. Most such cases manifest as leukemic, non-nodal MCL or gastrointestinal tract (GI)-only MCL, but some patients with nodal MCL also have an indolent natural history (especially those with low nodal tumor burden, low serum lactate dehydrogenase [LDH], and low Ki-67 index). Management of indolent MCL is discussed below. (See <a class="local">'Indolent MCL'</a> below.)</p><p>Patients who have nodal MCL with mutated <em>TP53</em>, blastoid morphology, or central nervous system involvement often experience inferior outcomes using standard treatments [<a href="#rid19">19</a>]. We strongly encourage such patients to participate in a clinical trial. (See <a class="local">'MCL with adverse features'</a> below.)</p><p>We consider the following induction regimens acceptable for fit, younger patients with MCL:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a><strong> plus </strong><a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">bendamustine</a><strong> (R-B)</strong> (see <a class="local">'Rituximab-bendamustine (R-B)'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>More intensive HiDAc-containing regimens </strong>(see <a class="local">'Intensive induction regimens'</a> below)   </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>R-B/R-HiDAC</strong> – R-B followed by <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> plus HiDAc (see <a class="local">'R-B/R-HiDAc'</a> below)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>R-DHAP</strong> – <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a>, <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>, HiDAc, plus <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a>, or <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> (see <a class="local">'R-DHAP'</a> below)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>R-CHOP/R-DHAP</strong> – <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (R-CHOP), alternating with R-DHAP (which can include <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a>, or <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a>) (see <a class="local">'R-CHOP/R-DHAP'</a> below)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nordic regimen</strong> – <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> plus maxi-CHOP (dose-intensified CHOP), alternating with R-HiDAc (see <a class="local">'Nordic regimen'</a> below)</p><p></p><p>There is disagreement about the contribution of the induction regimen to long-term outcomes in patients who subsequently undergo autologous HCT. Some experts favor induction using R-B because of its balance of efficacy and modest toxicity. Other experts favor more intensive, HiDAc-containing regimens; such regimens are more toxic than R-B, but there is uncertainty about whether transplanted patients experience similar or modestly improved long-term outcomes compared with those who received R-B induction [<a href="#rid20">20,21</a>]. </p><p>Management of MCL is evolving and we await results of ongoing randomized clinical trials for treatment of MCL, including studies that incorporate a Bruton tyrosine kinase inhibitor (BTKi) into induction therapy. As an example, in the TRIANGLE trial, patients were randomly assigned to one of three arms: R-CHOP/R-DHAP followed by autologous HCT; R-CHOP/R-DHAP plus <a class="drug drug_general" data-topicid="91587" href="/z/d/drug information/91587.html" rel="external">ibrutinib</a> followed by autologous HCT; and R-CHOP/R-DHAP plus ibrutinib without transplantation. This trial also incorporates ibrutinib into post-induction management and will evaluate the role of autologous HCT as consolidation therapy. Before endorsing such an approach, we await publication of this and other ongoing trials of front-line therapy for MCL.</p><p>We <strong>do not favor</strong> induction therapy using either R-CHOP alone or R-HyperCVAD. Randomized trials demonstrated that R-CHOP was less effective than either R-B or R-CHOP/R-DHAP, while R-HyperCVAD is associated with excessive toxicity and impaired stem cell collection, as described below.</p><p>No randomized trials have directly compared the various preferred induction regimens described above, but long-term outcomes after autologous HCT are similar and are presented below. (See <a class="local">'Rituximab-bendamustine (R-B)'</a> below and <a class="local">'Intensive induction regimens'</a> below.)</p><p>The following studies support our treatment preferences:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>R-B is less toxic than</strong> <strong>R-HyperCVAD </strong>– SWOG S1106 is the only trial of MCL that randomly assigned patients to induction therapy using R-B versus a more intensive regimen; the trial was closed early because R-HyperCVAD was associated with excessive toxicity and inadequate mobilization of stem cells for transplantation [<a href="#rid22">22</a>]. R-HyperCVAD caused more grade ≥3 anemia, neutropenia, and thrombocytopenia and nearly one-third of patients failed to mobilize even 1.5 x<sup> </sup>10<sup>6</sup> stem cells. Among patients on the R-HyperCVAD arm, 7 of 17 did not complete the planned course of induction therapy, compared with 8 of 35 on the R-B arm. Longer-term follow-up of the 52 evaluable patients (of 160 planned enrollees) reported no significant differences in two-year OS or PFS between trial arms [<a href="#rid23">23</a>]. </p><p></p><p class="bulletIndent1">A population-based study reported that long-term outcomes were similar between patients &lt;65 years who underwent autologous HCT after induction with R-CHOP versus R-HyperCVAD; however, R-HyperCVAD was associated with more adverse events, including unplanned hospital admissions for febrile neutropenia [<a href="#rid20">20</a>].  </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes with R-B are superior to R-CHOP or R-CVP</strong> – R-B achieved superior progression-free survival (PFS) with less toxicity when it was directly compared with R-CHOP or R-CVP (<a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>) in the randomized StiL [<a href="#rid24">24</a>] and BRIGHT [<a href="#rid25">25,26</a>] trials of patients with MCL and indolent lymphomas. Details of the StiL and BRIGHT trials are presented below. (See <a class="local">'Rituximab-bendamustine (R-B)'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of high-dose </strong><a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">cytarabine</a><strong> (HiDAc)</strong> – The importance of HiDAc was demonstrated in the MCL-Younger trial, in which 497 patients ≤65 years who were to undergo autologous HCT were first randomly assigned to six cycles of R-CHOP versus three cycles each of R-CHOP alternating with R-DHAP (which includes HiDAc) [<a href="#rid27">27</a>]. When adjusted for MIPI (Mantle cell lymphoma International Prognostic Index [MIPI]) prognostic score and with &gt;10 year follow-up, R-CHOP/R-DHAP achieved superior overall survival (OS; median not reached versus 11.3 years; hazard ratio [HR] 0.74 [95% CI 0.56-0.98]) and longer median time to treatment failure (TTF; 8.4 versus 3.9 years) [<a href="#rid28">28</a>]. There was a trend to more secondary hematologic malignancies in the R-CHOP/R-DHAP arm (4.5 versus 1.4 percent at 10 years). </p><p></p><p class="headingAnchor" id="H3398152367"><span class="h2">Response assessment</span><span class="headingEndMark"> — </span>After completing induction therapy, we assess treatment response using positron emission tomography (PET), scored according to the five-point PET scale (Deauville score)  (<a class="graphic graphic_table graphicRef108973" href="/z/d/graphic/108973.html" rel="external">table 2</a>) and Lugano criteria [<a href="#rid1">1</a>].</p><p>Treatment response is judged as follows: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complete response (CR)</strong> – PET score 0 to 3 (with or without a residual mass) and no evidence of bone marrow involvement</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Partial response (PR) </strong>– PET score 4 or 5 (with reduced uptake compared with baseline), no new progressive lesions, and bone marrow activity less than baseline </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>No response </strong>– PET score 4 or 5 (unchanged from baseline), no new lesions, and bone marrow activity unchanged from baseline</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Progressive disease – </strong>PET score 4 or 5 (increased compared with baseline), new sites of disease, and new or recurrent bone marrow activity </p><p></p><p>Outside of a clinical study, we do not routinely assess measurable residual disease (MRD) after completion of induction therapy for MCL. We await results of an ongoing phase 3 clinical trial (E4151; NCT03267433) that uses MRD to guide post-induction management of MCL. </p><p class="headingAnchor" id="H2794081212"><span class="h2">Post-induction management</span><span class="headingEndMark"> — </span>Subsequent management of MCL for transplant-eligible patients is guided by the response to induction therapy  (<a class="graphic graphic_algorithm graphicRef141184" href="/z/d/graphic/141184.html" rel="external">algorithm 1</a>). (See <a class="local">'Response assessment'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complete response (CR)</strong> – For patients who achieve CR, we proceed to consolidation therapy, as described below. (See <a class="local">'Consolidation therapy'</a> below.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Less than CR</strong> – For patients who do not achieve CR to induction therapy, we treat for relapsed or refractory (r/r) MCL, as described separately. (See  <a class="medical medical_review" href="/z/d/html/4735.html" rel="external">"Treatment of relapsed or refractory mantle cell lymphoma"</a>.)</p><p></p><p class="headingAnchor" id="H349149545"><span class="h3">Consolidation therapy</span><span class="headingEndMark"> — </span>For fit, younger patients who achieve CR after induction therapy, we suggest consolidation using autologous hematopoietic cell transplantation (HCT), rather than proceeding directly to maintenance therapy or observation alone  (<a class="graphic graphic_algorithm graphicRef141184" href="/z/d/graphic/141184.html" rel="external">algorithm 1</a>). This suggestion is based on superior survival and acceptable toxicity with autologous HCT. (See <a class="local">'Autologous transplantation'</a> below.) </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autologous transplantation versus maintenance therapy</strong> – The European MCL Network trial randomly assigned patients ≤65 years with advanced stage MCL to autologous HCT versus maintenance therapy using interferon alfa (IFNa) [<a href="#rid29">29</a>]. With 14-year median follow-up, transplantation achieved superior overall survival (OS; 7.5 versus 4.8 years; hazard ratio [HR] 0.66 [95% CI 0.46-0.95]) and superior progression-free survival (PFS; 3.3 versus 1.5 years; HR 0.50 [95% CI 0.36-0.69]) [<a href="#rid30">30</a>]. Patients in this trial were randomly assigned to induction therapy with CHOP (<a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>) versus R-CHOP (rituximab added to CHOP). Importantly, only patients who initially received CHOP had superior OS (HR 0.52 [95% CI 0.33–0.82]) and PFS (HR 0.40 [95% CI 0.26–0.61]) with autologous HCT compared with IFNa; there were no significant differences in OS or PFS between autologous HCT and maintenance IFNa therapy for patients who initially received R-CHOP.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autologous transplantation versus no transplantation</strong> – Analysis of the Swedish and Danish lymphoma registries reported that 273 of 1389 patients diagnosed with MCL from 2000 to 2011 underwent autologous HCT [<a href="#rid31">31</a>]. Compared with patients who received systemic therapy without transplantation, survival was superior for patients who underwent autologous HCT (HR 0.55 [95% CI 0.37-0.83]).</p><p></p><p>It is uncertain if autologous HCT can cure MCL. In one study, with median follow-up of 6.5 years (some patients were followed for 10 years), median event-free survival (EFS) was 7.4 years, but relapses occurred as long as 9 years after transplantation [<a href="#rid10">10</a>]. In another study, among 1029 patients &lt;65 years who were followed for a median of 6.3 years (and up to 17 years), compared with patients who were not transplanted, autologous HCT transplantation was associated with superior OS and PFS, but there was no plateau on either curve, indicating continued late relapses [<a href="#rid32">32</a>]. </p><p class="headingAnchor" id="H2084024948"><span class="h3">Post-transplant maintenance therapy</span><span class="headingEndMark"> — </span>Following autologous HCT for MCL, we suggest post-transplantation maintenance therapy using <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>  (<a class="graphic graphic_algorithm graphicRef141184" href="/z/d/graphic/141184.html" rel="external">algorithm 1</a>), rather than <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> maintenance or observation alone, based on superior survival and acceptable toxicity in randomized trials.</p><p>Many experts obtain a repeat PET scan at day 100 after transplantation; for patients who remain in CR, we proceed to maintenance therapy, while patients who have disease progression are treated for relapsed/refractory MCL. Some experts proceed directly to maintenance therapy without a repeat PET. Management of relapsed/refractory MCL is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4735.html" rel="external">"Treatment of relapsed or refractory mantle cell lymphoma"</a>.)</p><p><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> maintenance therapy is given at 375 mg/m<sup>2</sup> every two months for three years [<a href="#rid33">33</a>]. Rituximab is associated with the risk of infusion reactions and immunosuppression, and there is a risk of hepatitis B reactivation in patients who are positive for HbsAg or anti-HBc. (See  <a class="medical medical_review" href="/z/d/html/2811.html" rel="external">"Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy", section on 'Rituximab'</a> and  <a class="medical medical_review" href="/z/d/html/3939.html" rel="external">"Secondary immunodeficiency induced by biologic therapies", section on 'Rituximab'</a> and  <a class="medical medical_review" href="/z/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy", section on 'Type of immunosuppressive therapy'</a>.)</p><p>Trials that evaluated maintenance therapy following autologous HCT include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a><strong> maintenance versus observation</strong> – The following phase 3 trials demonstrated a survival advantage with rituximab maintenance versus observation after transplantation for MCL:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>LYSA</strong> – The phase 3 Lymphoma Study Association (LYSA) trial of 240 patients who underwent autologous HCT for MCL reported that three years of post-transplant <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> maintenance therapy achieved superior survival, compared with observation alone [<a href="#rid33">33</a>]. Patients received induction therapy with four cycles of R-DHAP (rituximab, <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>, high dose <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">cytarabine</a>, plus a platinum compound), followed by autologous HCT; they were then randomly assigned to three years of maintenance rituximab versus observation. With median follow-up &gt;4 years since transplantation, rituximab achieved superior four-year OS (89 percent [95% CI 81-94] versus 80 percent [95% CI 72-88]; hazard ratio [HR] 0.50 [95% CI 0.26-0.99]) and superior four-year PFS (83 percent [95% CI 73-88] versus 64 percent [95% CI 55-73]; HR 0.40 [95% CI 0.23-0.68]). There was no significant difference in grade ≥3 adverse effects (AEs) between the trial arms.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nordic</strong> – For patients treated with the Nordic MCL induction regimen who underwent autologous HCT, post-transplant <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> maintenance was superior to observation [<a href="#rid34">34</a>]. Among 112 transplanted patients, compared with observation, rituximab maintenance was associated with superior five-year PFS (73 versus 68 percent; HR 0.36 [95% CI 0.20-0.84]), but five-year OS was 78 percent in both arms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">Lenalidomide</a><strong> maintenance versus observation</strong> – In a randomized trial that compared lenalidomide maintenance versus observation after autologous HCT, lenalidomide achieved superior PFS, but it is generally not used because it caused excessive toxicity [<a href="#rid35">35</a>]. Notably, only one-half of patients completed their assigned lenalidomide maintenance therapy, mostly due to excessive adverse events. There was no statistically significant difference in three-year OS (93 versus 86 percent), but three-year PFS was superior with lenalidomide (80 percent versus 64 percent; HR 0.51 [95% CI 0.3-.087]). Lenalidomide was associated with more grade ≥3 neutropenia (59 versus 11 percent), nonhematologic AEs (31 versus 8 percent, mostly infections), and secondary malignancies (5 percent versus 3 percent; none were fatal).</p><p></p><p>Monitoring for disease relapse after completion of maintenance therapy is described below. (See <a class="local">'Monitoring'</a> below.)</p><p class="headingAnchor" id="H104392611"><span class="h1">OLDER OR LESS-FIT PATIENTS</span><span class="headingEndMark"> — </span>For patients who are not eligible for autologous transplantation because of age (eg, ≥65 years), comorbid conditions, or limited fitness, we treat with lower-intensity chemoimmunotherapy and maintenance therapy to control symptoms, reduce the burden of disease, and prolong survival. </p><p class="headingAnchor" id="H1106305903"><span class="h2">Induction for older or less-fit patients</span><span class="headingEndMark"> — </span>There is no consensus regimen in this setting; our preferred options include:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a><strong> plus </strong><a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">bendamustine</a> (R-B) (see <a class="local">'Rituximab-bendamustine (R-B)'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>VR-CAP</strong> – <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">Bortezomib</a>, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (see <a class="local">'VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin, prednisone)'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> <strong>plus</strong> l<strong>enalidomide</strong> (see <a class="local">'Rituximab plus lenalidomide'</a> below)</p><p></p><p>No studies have directly compared outcomes with these regimens and the preferred treatment approach varies among clinicians. Administration and outcomes with these regimens are presented below. (See <a class="local">'Rituximab-bendamustine (R-B)'</a> below and <a class="local">'Lower-intensity regimens'</a> below.)</p><p>Treatment that includes a Bruton tyrosine kinase inhibitor (BTKi) is also an option in this setting, but these agents are not currently approved for initial therapy of MCL.</p><p class="headingAnchor" id="H2205736349"><span class="h2">Maintenance therapy</span><span class="headingEndMark"> — </span>Post-induction management is guided by the response to induction therapy, as described above (see <a class="local">'Response assessment'</a> above):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complete response (CR) or partial response (PR)</strong> – For older/less-fit patients with a CR or PR after induction therapy, we suggest <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> maintenance therapy, rather than maintenance therapy using interferon (IFN) alfa, based on superior survival and little toxicity in a randomized trial and in other studies.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> maintenance therapy is given at 375 mg/m<sup>2</sup> every two months for three years [<a href="#rid33">33</a>]. Rituximab is associated with the risk of infusion reactions and immunosuppression, and there is a risk of hepatitis B reactivation in patients who are positive for HBsAg or anti-HBc. (See  <a class="medical medical_review" href="/z/d/html/2811.html" rel="external">"Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy", section on 'Rituximab'</a> and  <a class="medical medical_review" href="/z/d/html/3939.html" rel="external">"Secondary immunodeficiency induced by biologic therapies", section on 'Rituximab'</a> and  <a class="medical medical_review" href="/z/d/html/3649.html" rel="external">"Hepatitis B virus reactivation associated with immunosuppressive therapy", section on 'Type of immunosuppressive therapy'</a>.)</p><p></p><p class="bulletIndent1">Studies of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> maintenance therapy for older or less fit patients after induction therapy include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>MCL-Elderly</strong> – The phase 3 MCL-Elderly trial reported that maintenance <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> achieved superior survival compared with maintenance IFNa in patients who were not eligible for transplantation [<a href="#rid36">36</a>]. In this trial, 274 patients &gt;60 years were first randomly assigned to induction therapy with <a class="drug drug_general" data-topicid="8452" href="/z/d/drug information/8452.html" rel="external">fludarabine</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, and rituximab (R-FC) versus R-CHOP; patients who achieved CR or PR after induction therapy were again randomly assigned to maintenance therapy using rituximab versus IFNa. Compared with IFNa, rituximab reduced the risk of progression or death (HR 0.55 [95% CI 0.36-0.87]), with a trend toward improved four-year OS (87 versus 63 percent); rituximab was associated with grade ≥3 leukopenia and infections in &lt;5 percent of patients. More than one-half of patients continued rituximab maintenance for ≥2 years and one-third continued it for ≥5 years. With longer follow-up (median eight years), rituximab maintenance achieved significantly superior OS (9.8 versus 6.4 years, respectively) and PFS (5.2 versus 2.0 years); the benefits of rituximab maintenance were even greater for patients who received R-CHOP rather than R-FC induction therapy [<a href="#rid37">37</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Flatiron database</strong> – Maintenance <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> was associated with improved outcomes compared with observation alone, according to retrospective analysis of 4216 patients treated in community settings in the Flatiron electronic record-derived database [<a href="#rid38">38</a>]. Compared with observation, maintenance rituximab was associated with superior OS (HR 1.51 [95% CI 1.19-1.92]) and longer time to next treatment (HR 1.96 [95% CI 1.61-2.38]). The superior efficacy of maintenance rituximab was validated in an independent cohort of 1168 patients treated in academic medical centers; among these patients, rates of OS were 92 versus 73 percent for rituximab maintenance versus observation, respectively, and rates of PFS were 74 versus 49 percent, respectively. </p><p></p><p class="bulletIndent1">Some experts do not offer <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> maintenance to patients who received induction therapy with R-B, based on preliminary results from the StiL NHL-7 MAINTAIN trial, reported only as an abstract (in 1996) [<a href="#rid39">39</a>]. After nearly five years of follow-up of 168 patients who received R-B induction therapy, two years of rituximab maintenance did not achieve a survival advantage, compared with observation alone. We await publication of these results before concluding that rituximab maintenance does not improve outcomes in patients treated with R-B<em>. </em></p><p></p><p class="bulletIndent1">We also await results from ongoing phase 3 trials of maintenance therapy in this setting, including ECOG-ACRIN E1411 (NCT01415752) and MCL-R2 Elderly (NCT01865110). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Stable or progressive disease</strong> – For older or less-fit patients who have stable disease or progressive disease after induction therapy, we treat for refractory MCL, as described separately. (See  <a class="medical medical_review" href="/z/d/html/4735.html" rel="external">"Treatment of relapsed or refractory mantle cell lymphoma"</a>.)</p><p></p><p class="headingAnchor" id="H3441245121"><span class="h1">SPECIAL POPULATIONS</span><span class="headingEndMark"> — </span>Management of patients with the following presentations differs from that of advanced-stage nodal MCL.</p><p class="headingAnchor" id="H1155031856"><span class="h2">Indolent MCL</span><span class="headingEndMark"> — </span>For asymptomatic patients with indolent MCL, we suggest initial observation rather than immediate treatment, based on favorable outcomes in retrospective studies, the opportunity to delay or avoid treatment-related adverse effects (AEs), and absence of evidence that delayed initiation of treatment affects disease response.</p><p>Most often, indolent MCL manifests as leukemic, non-nodal MCL or gastrointestinal tract (GI)-only MCL, but selected cases of nodal MCL may also have an indolent natural history (eg, low nodal tumor burden, low serum lactate dehydrogenase [LDH], and low Ki-67 index). </p><p>Studies of observation in selected asymptomatic patients with MCL include: </p><p class="bulletIndent1"><span class="glyph">●</span>In a single center study, initial observation was used for 22 percent (90 of 404) of patients with MCL [<a href="#rid40">40</a>]. Among the patients who underwent initial observation, 91 percent had advanced-stage disease, including bone marrow involvement in 72 percent, leukemic involvement (ie, absolute lymphocyte count &gt;5 x 10<sup>9</sup>/L) in 26 percent, and 20 percent with ≥2 sites of extranodal involvement. Expectant monitoring continued for ≥6 months in 93 percent of the observed patients, while 71 percent ultimately received therapy (after a median of 23 months). Pathologic features did not predict the duration of observation; Ki-67 was ≥30 percent in one-quarter of the patients who were observed, while 3 of 25 observed patients had mutated <em>TP53</em>; none of the observed patients had the blastoid variant of MCL. Among the 30 patients who were observed for ≥2 years, 17 had a low tumor burden without leukemic involvement; 9 had leukemic disease with minimal nodal disease, with or without splenomegaly; and 4 had GI tract-only disease. Compared with treated patients, the observed patients had superior overall survival (OS; 11.4 years versus 9.4 years), but there was no difference when comparing time from start of treatment to death, suggesting that the longer survival of observed patients was not related to greater treatment sensitivity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another single institution study, one-third of 97 patients were monitored for ≥3 months before beginning systemic therapy [<a href="#rid41">41</a>]. Among patients who underwent initial observation, median time to initial treatment was 12 months (range 4 to 128 months). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a population-based study, 17 percent of patients were managed with observation alone for ≥3 months [<a href="#rid42">42</a>]. Among the observation-only patients, 80 percent were monitored expectantly for ≥1 year and 13 percent were observed for &gt;5 years; median time to first treatment was 35 months (range 5-79 months). More than two-thirds of observed patients had nodal presentations. Median OS was longer in the observation group compared with the early treatment group (72 versus 53 months), but multivariable analysis reported that treatment was not associated with improved OS. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Initial observation (ie, treatment deferred &gt;90 days from diagnosis) was used for 6 percent of 8029 patients in the US National Cancer Database; median time to initial treatment was 121 days (range, 91 to 1153 days) [<a href="#rid43">43</a>]. Patients who deferred therapy were more likely to have stage I or II disease or extranodal involvement, and they were less likely to have B symptoms. Another population-based study reported initial observation in 2.4 percent of 1389 patients with MCL [<a href="#rid31">31</a>].</p><p></p><p>Some asymptomatic patients may choose early treatment rather than observation. If so, treatment is similar to that for older or less-fit patients, as described above. (See <a class="local">'Older or less-fit patients'</a> above.)</p><p class="headingAnchor" id="H1225177674"><span class="h2">Stage I MCL</span><span class="headingEndMark"> — </span>Stage I MCL is extremely rare; most cases of suspected stage I MCL have subclinical disease at other sites, as discussed above. (See <a class="local">'Disease stage'</a> above.)</p><p>We generally use radiation therapy for patients with documented stage I MCL to relieve symptoms and control disease at that site. </p><p>In a retrospective study of 26 patients with limited-stage MCL, those treated with RT (with or without chemotherapy) had improved five-year progression-free survival (PFS; 73 percent versus 13 percent) and a trend towards improved overall survival (OS) compared with patients who did not receive RT [<a href="#rid44">44</a>]. Six of 17 patients treated with RT were alive without disease progression at &gt;5 years. </p><p class="headingAnchor" id="H453841126"><span class="h2">MCL with adverse features</span><span class="headingEndMark"> — </span>Patients with MCL with mutated <em>TP53</em>, central nervous system involvement, or blastoid morphology generally have poor outcomes with conventional treatment, including autologous hematopoietic cell transplantation (HCT) [<a href="#rid19">19</a>]. We strongly encourage such patients to participate in a clinical trial; information and instructions for referring a patient in the US to an appropriate research center can be obtained from <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2F&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSzRV8srxVomMWotD038y2Xv&amp;TOPIC_ID=4719" target="_blank">https://www.clinicaltrials.gov/</a>. </p><p>Outside of a clinical trial, treatment of MCL with adverse features should focus on symptom relief, reducing disease burden, and prolonging survival, while limiting excessive treatment-related adverse effects. We generally avoid autologous hematopoietic cell transplantation (HCT) in this setting because there is no evidence that it improves long-term outcomes for these patients.</p><p>Our approach for treatment of MCL with adverse features follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Induction therapy</strong> – We generally treat using R-B or another lower-intensity induction chemoimmunotherapy regimen:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Rituximab-bendamustine (R-B)</strong> – (See <a class="local">'Rituximab-bendamustine (R-B)'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other lower-intensity regimens</strong> – (See <a class="local">'Lower-intensity regimens'</a> below.)</p><p></p><p class="bulletIndent1">There are few studies of treatment outcomes in this higher-risk population of patients. Studies that included patients of all ages or used heterogeneous treatment regimens in this setting reported inferior outcomes in patients with mutated <em>TP53</em> or complex karyotype [<a href="#rid45">45-51</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Avoidance of autologous HCT</strong> – Among 183 patients ≤65 years with MCL in the Nordic MCL2 and MCL3 trials who were treated with intensive induction therapy followed by autologous HCT, <em>TP53</em> mutations were independently associated with inferior outcomes; mutated <em>TP53</em> was found in 11 percent of patients in these trials [<a href="#rid19">19</a>]. With median follow-up of 9.2 years, compared with no <em>TP53</em> mutation, patients with mutated <em>TP53 </em>had 1.8-year median OS (versus median not reached), 0.9-year median PFS (versus median 10.2 years), and 1.0-year median time to relapse (versus 12.3 years). Mutated <em>TP53</em> was independently associated with inferior OS (HR 6.2 [95% CI 2.6-14.9]), PFS (HR 6.8 [95% CI 3.4-13.8]), and cumulative incidence of relapse (HR 6.9 [95% 3.3-14.5]) in multivariate analysis. Blastoid variant and Ki-67 index ≥30 percent were associated with inferior outcomes, but they were not independently associated with decreased survival. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Maintenance therapy</strong> – For patients who achieve CR, we treat with maintenance <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, as described above. (See <a class="local">'Maintenance therapy'</a> above.)</p><p></p><p>Allogeneic HCT has been associated with long term disease control in patients who have MCL with adverse features, but this benefit must be weighed against the short-term and long-term adverse effects of allogeneic transplantation. It should be noted that the following studies preceded use of chimeric antigen receptor (CAR)-T cell therapy for management of relapsed or refractory MCL. (See  <a class="medical medical_review" href="/z/d/html/4735.html" rel="external">"Treatment of relapsed or refractory mantle cell lymphoma"</a>.)</p><p>Among 42 patients (median age 61 years; range 34 to 74 years) who underwent non-myeloablative or reduced intensity conditioning allogeneic HCT for MCL in a single-institution study, two-year OS was 78 percent (95% CI 60-88 percent), two-year PFS was 61 percent (95% CI 43-75 percent), relapse rate was 19 percent, and non-relapse mortality was 20 percent [<a href="#rid52">52</a>]. There was no difference in OS or relapse rate when comparing post-allogeneic HCT outcomes among patients who had mutated <em>TP53</em> versus those without mutant <em>TP53</em>. This observation has been interpreted by some to indicate that allogeneic HCT can overcome the negative prognostic impact of mutated <em>TP53</em> (in contrast with outcomes after autologous HCT) [<a href="#rid19">19</a>]. These results are comparable with other published reports on allogenic HCT in MCL patients [<a href="#rid53">53,54</a>]. </p><p class="headingAnchor" id="H1906257970"><span class="h1">MONITORING</span><span class="headingEndMark"> — </span>Following completion of therapy, we restage patients with positron emission tomography (PET) and monitor for relapse and treatment-related complications. </p><p>The frequency and nature of follow-up visits is influenced by preferences of the patient and physician. No prospective studies have compared various follow-up protocols. </p><p>Relapses of MCL can continue long after completion of therapy, including after autologous transplantation; as described above, there is no clear plateau for survival or relapse after transplantation. (See <a class="local">'Consolidation therapy'</a> above.)</p><p>Our approach to monitoring patients with MCL follows:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical</strong> – History, physical examination, and laboratory studies are scheduled every two or three months in the first year, every three to six months in the second year, and then every 6 to 12 months for at least five years. Subsequent follow-up is yearly, or as clinically indicated </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Imaging</strong> – We limit the number of imaging studies, particularly in younger individuals, given concerns about radiation exposure and the risk for second malignancies. (See  <a class="medical medical_review" href="/z/d/html/14613.html" rel="external">"Radiation-related risks of imaging"</a>.)</p><p></p><p class="bulletIndent1">We generally perform imaging as clinically indicated (ie, for new or progressive symptoms or other evidence of progression). Some experts instead favor routine surveillance. Because most relapses occur in the first two to four years after treatment, an example of surveillance imaging might be contrast-enhanced computed tomography (CT) of chest, abdomen, and pelvis no more than every six months for the first two years, and then no more than annually for two additional years.</p><p></p><p>Relapse can be suggested by clinical evaluation or imaging, but it must be confirmed by biopsy. Management of relapsed MCL is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4735.html" rel="external">"Treatment of relapsed or refractory mantle cell lymphoma"</a>.)</p><p class="headingAnchor" id="H3401851449"><span class="h1">CHEMOIMMUNOTHERAPY REGIMENS</span><span class="headingEndMark"> — </span>The choice of initial chemoimmunotherapy is guided by clinical presentation and medical fitness, as described above. (See <a class="local">'Overview of management'</a> above.)</p><p class="headingAnchor" id="H3262324471"><span class="h2">Rituximab-bendamustine (R-B)</span><span class="headingEndMark"> — </span>Rituximab-bendamustine (R-B) is one of the preferred induction regimens for patients with nodal MCL (See <a class="local">'Induction therapy for fit, younger patients'</a> above and <a class="local">'Induction for older or less-fit patients'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration</strong> – Up to six cycles of: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">Bendamustine</a> – 90 mg/m² intravenously over 30–60 minutes on days 1 and 2 of a four-week cycle</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> – 375 mg/m² intravenously on day 1 of each cycle</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcomes</strong> – In the randomized StiL and BRIGHT trials, R-B achieved improved progression-free survival (PFS) and less toxicity, when directly compared with R-CHOP (<a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>) [<a href="#rid24">24,25</a>]. R-B was less toxic and had similar efficacy when compared with R-HyperCVAD (rituximab, hyperfractionated cyclophosphamide, vincristine, <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>, alternating with high-dose <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> and <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">cytarabine</a>) in another phase 3 trial (SWOG S1106) [<a href="#rid22">22,23</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>StiL</strong> – The randomized StiL (Study Group Indolent Lymphomas) trial compared R-B versus R-CHOP as first-line therapy in patients with advanced MCL, follicular, and indolent B cell lymphomas; MCL accounted for 18 percent of 514 patients [<a href="#rid24">24</a>]. Among patients with MCL, median progression-free survival (PFS) was higher with R-B than R-CHOP (35 months versus 22 months). R-B was also associated with fewer serious AEs (19 versus 29 percent) and less grade ≥3 neutropenia (29 versus 69 percent), peripheral neuropathy (all grades; 7 versus 29 percent), and infectious complications (all grades; 37 versus 50 percent). Fatal sepsis occurred in one patient treated with R-B and five patients in the R-CHOP arm and the incidence of second cancers was similar (8 versus 9 percent, respectively). Notably, data from more than one-half of patients in the trial were censored before the minimum period of follow-up. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>BRIGHT</strong> – The phase 3 BRIGHT trial, which included 447 patients with MCL and indolent lymphomas, reported that R-B achieved superior PFS and response rates compared with R-CHOP or R-CVP (<a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>), but there was no difference in OS [<a href="#rid25">25,26</a>]. Patients were randomly assigned to R-B versus pre-selected R-CHOP or R-CVP. Among the 64 patients with MCL, R-B achieved superior overall response rate (ORR; 94 versus 85 percent) and complete responses (CR; 50 versus 27 percent) [<a href="#rid26">26</a>]. With longer follow-up, R-B achieved superior five-year PFS (66 versus 56 percent; hazard ratio [HR] 0.61 [95% CI 0.45-0.85]) [<a href="#rid25">25</a>]. R-CHOP/R-CVP was associated with more grade ≥3 neutropenia (54 versus 38 percent, respectively), but similar rates of grade ≥3 infections (6 versus 9 percent, respectively). There were more secondary malignancies (mostly skin cancers) with R-B compared with R-CHOP/R-CVP (five patients versus three patients).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>SWOG S1106</strong> – This trial, which randomly assigned patients to induction therapy using R-B versus R-HyperCVAD was closed early because R-HyperCVAD caused excessive toxicity and inadequate mobilization of stem cells for transplantation [<a href="#rid22">22</a>]. Rates of two-year OS and PFS were similar between trial arms among the 52 evaluable patients (of 160 planned enrollees) who completed therapy [<a href="#rid23">23</a>]. </p><p></p><p class="headingAnchor" id="H3995426029"><span class="h2">Intensive induction regimens</span><span class="headingEndMark"> — </span>There is no consensus intensive regimen for MCL. Each of the preferred, high-dose <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">cytarabine</a> (HiDAc)-containing intensive regimens is associated with high rates of response, but substantial toxicity in younger, fit patients with MCL. No randomized trials have directly compared these regimens and the preferred treatment varies among institutions and clinicians. </p><p>We consider any of the following intensive regimens acceptable for induction therapy of nodal MCL, as discussed above (see <a class="local">'Fit, younger patients'</a> above):</p><p class="bulletIndent2"><span class="glyph">•</span><strong>R-B/R-HiDAc</strong> – Rituximab-bendamustine (R-B) followed by <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> plus HiDAc</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>R-DHAP</strong> – <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a>, <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>, HiDAc, <strong>plus</strong> <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a>, <strong>or</strong> <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>R-CHOP/R-DHAP</strong> – <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (R-CHOP), alternating with R-DHAP (six cycles total)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nordic regimen</strong> – <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> plus maxi-CHOP (dose-intensified CHOP), alternating with R-HiDAc</p><p></p><p>We <strong>do not favor</strong> induction therapy using R-HyperCVAD (<a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, hyperfractionated <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>, alternating with high-dose <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> and <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">cytarabine</a>). This judgement is based on a randomized trial of R-B versus R-HyperCVAD that was terminated early because HyperCVAD caused excessive toxicity and impaired stem cell collection [<a href="#rid22">22</a>]. Furthermore, in patients with MCL who subsequently underwent autologous HCT, R-HyperCVAD induction was associated similar survival but excess toxicity when compared with compared with induction using R-CHOP (rituximab, cyclophosphamide, <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, vincristine, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>) in a population-based study [<a href="#rid20">20</a>]. (See <a class="local">'Fit, younger patients'</a> above.)</p><p class="headingAnchor" id="H1363397033"><span class="h3">R-B/R-HiDAc</span><span class="headingEndMark"> — </span>The R-B/R-HiDAc regimen comprises three cycles of R-B and three cycles of R-HiDAc. </p><p>Among 87 evaluable patients with MCL who were treated with R-B/R-HiDAc, followed by autologous hematopoietic cell transplantation (HCT), three-year OS and PFS were 92 and 83 percent, respectively [<a href="#rid55">55</a>]. Among enrolled patients, 92 percent completed induction therapy and 84 percent proceeded to autologous HCT. Induction therapy with R-B/R-HiDAc was associated with 97 percent ORR (90 percent CR). Grade ≥3 adverse events (AEs) included 85 percent thrombocytopenia, 83 percent neutropenia, and 15 percent febrile neutropenia; there were no treatment-related deaths during induction therapy. All 23 patients who were evaluated for measurable residual disease (MRD) were MRD-negative after transplantation; MRD subsequently became positive in only one patient (who later relapsed clinically). </p><p>In a study of 21 patients (42 to 69 years old) who underwent autologous HCT after R-B/R-HiDAc, after median follow-up of 13 months, median OS was not reached and PFS was 96 percent [<a href="#rid56">56</a>]. Among 15 patients who were evaluable for measurable residual disease (MRD), 93 percent were MRD-negative.</p><p class="headingAnchor" id="H3060663586"><span class="h3">R-DHAP</span><span class="headingEndMark"> — </span>This regimen comprises <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>, HiDAc, <strong>plus</strong> a platinum-based agent (ie, <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a>, <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a>, or <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a>).</p><p>Retrospective analysis of the LyMA trial, which treated with four cycles of R-DHAP induction therapy, reported that compared with <a class="drug drug_general" data-topicid="9271" href="/z/d/drug information/9271.html" rel="external">cisplatin</a> and <a class="drug drug_general" data-topicid="9202" href="/z/d/drug information/9202.html" rel="external">carboplatin</a>, outcomes were superior when <a class="drug drug_general" data-topicid="10180" href="/z/d/drug information/10180.html" rel="external">oxaliplatin</a> was used as platinum-based agent [<a href="#rid57">57</a>]. Among 298 enrolled patients, investigators were allowed to choose the platinum compound to be used in R-DHAP induction therapy; patients subsequently underwent autologous HCT. According to an intention-to-treat analysis, there was a trend toward superior four-year OS with carboplatin (92 percent in 38 patients), compared with 76 percent for patients treated with either cisplatin (184 patients) and carboplatin (76 patients); oxaliplatin was also associated with a trend toward superior four-year PFS (87 versus 65 percent for cisplatin/carboplatin) and improved CR. Oxaliplatin and carboplatin were better tolerated than cisplatin.</p><p class="headingAnchor" id="H3114385889"><span class="h3">R-CHOP/R-DHAP</span><span class="headingEndMark"> — </span>This regimen comprises alternating courses of R-CHOP (<a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>)  (<a class="graphic graphic_table graphicRef63586" href="/z/d/graphic/63586.html" rel="external">table 5</a>) and R-DHAP (six cycles total). </p><p>A phase 3 trial of 497 patients ≤65 years compared R-CHOP/R-DHAP versus six cycles of R-CHOP; each induction regimen was followed by autologous HCT [<a href="#rid27">27,28</a>]. With six-year median follow-up, survival was similar (76 percent five-year OS with R-CHOP/R-DHAP versus 69 percent with R-CHOP), but the alternating regimen achieved superior median time to treatment failure (TTF; not reached versus 9 years) and longer remission duration (84 months versus 49 months).</p><p>A phase 2 study of 60 patients treated with R-CHOP/R-DHAP followed by autologous HCT reported 75 percent five-year OS and 83 month median EFS; there were no treatment-related deaths [<a href="#rid58">58</a>]. </p><p class="headingAnchor" id="H404572924"><span class="h3">Nordic regimen</span><span class="headingEndMark"> — </span>This regimen comprises six cycles total of R-maxi-CHOP (which includes <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a> 1200 mg/m<sup>2</sup> and <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a> 75 mg/m<sup>2</sup>) alternating with R-HiDAc [<a href="#rid59">59</a>].</p><p>Among 160 patients treated with the Nordic MCL2 regimen, followed by autologous HCT, after follow-up &gt;11 years, median OS and PFS were 12.7 years and 8.5 years, respectively [<a href="#rid60">60</a>]. Survival curves did not reach a plateau, even after a decade of follow-up.</p><p class="headingAnchor" id="H3119239057"><span class="h2">Lower-intensity regimens</span><span class="headingEndMark"> — </span>We consider the following lower-intensity induction regimens suitable for patients with MCL who are not transplant-eligible. (See <a class="local">'Induction for older or less-fit patients'</a> above.)</p><p class="headingAnchor" id="H2437166180"><span class="h3">VR-CAP (bortezomib, rituximab, cyclophosphamide, doxorubicin, prednisone)</span><span class="headingEndMark"> — </span>In the VR-CAP regimen, <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> (1.3 mg/m<sup>2</sup> on days 1, 4, 8, and 11 of each cycle) replaces <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a> in R-CHOP  (<a class="graphic graphic_table graphicRef63586" href="/z/d/graphic/63586.html" rel="external">table 5</a>).</p><p>In the phase 3 LYM-3002 trial of 487 patients with MCL who were not eligible for transplantation, VR-CAP achieved superior survival compared with R-CHOP [<a href="#rid61">61,62</a>]. VR-CAP achieved longer median OS (91 months versus 56 months; HR 0.66 [95% CI 0.51-0.85]) and median PFS (25 versus 14 months; HR 0.63 [95% CI 0.50-0.79]), but more grade ≥3 AEs (93 versus 84 percent). Long-term follow-up reported one case of lung cancer and one case of gastric cancer in the VR-CAP group. A higher incidence of herpes zoster reactivation (5 versus 1 percent) with VR-CAP led to a protocol amendment to mandate antiviral prophylaxis. </p><p class="headingAnchor" id="H513506829"><span class="h3">Rituximab plus lenalidomide</span><span class="headingEndMark"> — </span>This regimen comprises:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">Rituximab</a> – 375 mg/m<sup>2</sup> once weekly for the first 4 weeks </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">Lenalidomide</a> – 20 mg daily on days 1 through 21 of every 28-day cycle for 12 cycles </p><p></p><p>In a study of 38 patients, rituximab-lenalidomide was associated with 87 percent ORR (including 61 percent CR) [<a href="#rid63">63</a>]. With median follow-up &gt;5 years, three-year OS and PFS were 90 and 80 percent, respectively, and estimated five year OS and PFS were 77 and 64 percent [<a href="#rid46">46</a>].</p><p>Addition of a third agent to rituximab-lenalidomide caused substantial toxicity. Addition of <a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">bendamustine</a> in 51 patients was associated with 42 percent grade ≥3 infections and second cancers in 16 percent [<a href="#rid64">64</a>]. Addition of <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">bortezomib</a> as a third agent was associated with 70 percent two-year PFS, but 51 percent of patients experienced grade ≥3 neutropenia [<a href="#rid65">65</a>].</p><p class="headingAnchor" id="H1765810628"><span class="h1">AUTOLOGOUS TRANSPLANTATION</span><span class="headingEndMark"> — </span>Autologous hematopoietic cell transplantation (HCT) is standard care for young, medically-fit patients who achieve a complete response (CR) after induction therapy for MCL. (See <a class="local">'Consolidation therapy'</a> above.)</p><p>The induction regimen for MCL does not clearly affect long-term outcomes after transplantation. As examples, similar post-HCT survival was reported when patients received induction therapy using R-B, R-B/R-HiDAc, and R-CHOP/R-HiDAc [<a href="#rid10">10,23,55</a>]. Long-term outcomes after autologous HCT are better when patients achieve a complete response (CR) to induction therapy [<a href="#rid66">66</a>]. Compared with autologous HCT, allogeneic HCT using reduced intensity conditioning in first remission offered no survival advantage in a population-based study [<a href="#rid67">67</a>]. </p><p>Maintenance therapy with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> after autologous HCT is discussed above. (See <a class="local">'Post-transplant maintenance therapy'</a> above.)</p><p class="headingAnchor" id="H2216314694"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/122016.html" rel="external">"Society guideline links: Management of mantle cell lymphoma"</a>.)</p><p class="headingAnchor" id="H14"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Description</strong> – Mantle cell lymphoma (MCL) is a B cell non-Hodgkin lymphoma (NHL) with features of both indolent and more aggressive NHL that has a heterogeneous natural history. MCL can involve lymph nodes and/or extranodal disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview of management</strong> – Most patients present with symptomatic advanced-stage (stages II-IV) classic MCL that requires treatment, but selected patients with indolent MCL may benefit from initial observation. Treatment of classic MCL generally includes induction therapy followed by consolidation and/or maintenance therapy. </p><p></p><p class="bulletIndent1">For patients with MCL who receive systemic therapy, we recommend treatment that includes <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> plus chemotherapy, rather than chemotherapy alone (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Overview of management'</a> above.) </p><p></p><p class="bulletIndent1">Management may differ for patients with indolent MCL, MCL with adverse pathologic features, and rare patients with stage I disease MCL. (See <a class="local">'Special populations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Younger, fit patients </strong>– Medically-fit patients ≤60 or ≤65 years who are suitable for autologous hematopoietic cell transplantation (HCT) (See <a class="local">'Fitness'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Induction therapy</strong> – For younger, fit patients with classic MCL, we suggest induction therapy using <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> plus <a class="drug drug_general" data-topicid="9323" href="/z/d/drug information/9323.html" rel="external">bendamustine</a> (R-B) or a more intensive regimen that includes high-dose <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">cytarabine</a> (HiDAc)  (<a class="graphic graphic_algorithm graphicRef141184" href="/z/d/graphic/141184.html" rel="external">algorithm 1</a>), rather than R-CHOP (rituximab, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">doxorubicin</a>, <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">vincristine</a>, <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>) or R-HyperCVAD (rituximab, hyperfractionated cyclophosphamide, vincristine, <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a>, alternating with high-dose <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a> and cytarabine) (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Induction therapy for fit, younger patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Consolidation</strong> – For younger, fit patients with a complete response (CR) to induction therapy, we suggest autologous HCT  (<a class="graphic graphic_algorithm graphicRef141184" href="/z/d/graphic/141184.html" rel="external">algorithm 1</a>), rather than observation or maintenance therapy alone (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Consolidation therapy'</a> above.)</p><p></p><p class="bulletIndent2">Autologous HCT is discussed above. (See <a class="local">'Autologous transplantation'</a> above.)</p><p></p><p class="bulletIndent2">For patients who did not achieve CR, we treat for relapsed/refractory (r/r) MCL. (See  <a class="medical medical_review" href="/z/d/html/4735.html" rel="external">"Treatment of relapsed or refractory mantle cell lymphoma"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Maintenance</strong> – After autologous HCT, we suggest three years of <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a> maintenance therapy  (<a class="graphic graphic_algorithm graphicRef141184" href="/z/d/graphic/141184.html" rel="external">algorithm 1</a>), rather than <a class="drug drug_general" data-topicid="9822" href="/z/d/drug information/9822.html" rel="external">lenalidomide</a> maintenance or observation alone (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Post-transplant maintenance therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Older or less-fit</strong> <strong>patients</strong> – Patients who are not suitable for autologous HCT (See <a class="local">'Older or less-fit patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Induction therapy</strong> – Preferred regimens for older, less-fit patients include are described above. (See <a class="local">'Induction for older or less-fit patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Maintenance therapy</strong> – For older, less-fit patients with CR or partial response (PR), we suggest three years of maintenance therapy with <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, rather than interferon alfa maintenance therapy or observation alone (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). </p><p></p><p class="bulletIndent2">For patients without CR/PR, we treat for r/r MCL. (See  <a class="medical medical_review" href="/z/d/html/4735.html" rel="external">"Treatment of relapsed or refractory mantle cell lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indolent MCL</strong> – For asymptomatic patients with indolent MCL, we suggest initial observation rather than immediate treatment (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Indolent MCL'</a> above.)</p><p></p><p class="bulletIndent1">Most cases of indolent MCL manifest as leukemic, non-nodal MCL or gastrointestinal tract-only disease, but selected cases of nodal MCL may also have an indolent natural history.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chemoimmunotherapy </strong>– Treatment of MCL varies according to age, fitness, institutional approach, and patient preference (see <a class="local">'Overview of management'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Regimens</strong> – Chemoimmunotherapy regimens for MCL include:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Rituximab-bendamustine</strong> (See <a class="local">'Rituximab-bendamustine (R-B)'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Intensive regimens</strong> – (See <a class="local">'Intensive induction regimens'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Lower-intensity regimens</strong> – (See <a class="local">'Lower-intensity regimens'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – Monitoring for relapse and treatment-related complications is discussed above. (See <a class="local">'Monitoring'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32:3059.</a></li><li><a class="nounderline abstract_t">Jain P, Zhang S, Kanagal-Shamanna R, et al. Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Adv 2020; 4:1038.</a></li><li><a class="nounderline abstract_t">Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood 2022; 140:1229.</a></li><li><a class="nounderline abstract_t">Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022; 36:1720.</a></li><li><a class="nounderline abstract_t">Royo C, Navarro A, Clot G, et al. Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease. Leukemia 2012; 26:1895.</a></li><li><a class="nounderline abstract_t">Hu Z, Sun Y, Schlette EJ, et al. CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course. Mod Pathol 2018; 31:327.</a></li><li><a class="nounderline abstract_t">Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111:558.</a></li><li><a class="nounderline abstract_t">Romaguera JE, Fayad LE, Feng L, et al. Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 2010; 150:200.</a></li><li><a class="nounderline abstract_t">Hoster E, Klapper W, Hermine O, et al. Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. J Clin Oncol 2014; 32:1338.</a></li><li><a class="nounderline abstract_t">Geisler CH, Kolstad A, Laurell A, et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol 2012; 158:355.</a></li><li><a class="nounderline abstract_t">Geisler CH, Kolstad A, Laurell A, et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood 2010; 115:1530.</a></li><li><a class="nounderline abstract_t">Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007; 99:706.</a></li><li><a class="nounderline abstract_t">Schulz H, Bohlius J, Skoetz N, et al. Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. Cochrane Database Syst Rev 2007; :CD003805.</a></li><li><a class="nounderline abstract_t">Griffiths R, Mikhael J, Gleeson M, et al. Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma. Blood 2011; 118:4808.</a></li><li><a class="nounderline abstract_t">Zelenetz AD, Gordon LI, Chang JE, et al. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021. J Natl Compr Canc Netw 2021; 19:1218.</a></li><li><a class="nounderline abstract_t">Munshi PN, Hamadani M, Kumar A, et al. ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma. Bone Marrow Transplant 2021; 56:2911.</a></li><li><a class="nounderline abstract_t">Linton K, Dreyling M. EHA Endorsement of ESMO Clinical Practice Guidelines for Newly Diagnosed and Relapsed Mantle Cell Lymphoma. Hemasphere 2020; 4:e464.</a></li><li><a class="nounderline abstract_t">Dreyling M, Campo E, Hermine O, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28:iv62.</a></li><li><a class="nounderline abstract_t">Eskelund CW, Dahl C, Hansen JW, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood 2017; 130:1903.</a></li><li><a class="nounderline abstract_t">LaCasce AS, Vandergrift JL, Rodriguez MA, et al. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood 2012; 119:2093.</a></li><li><a class="nounderline abstract_t">Martin P, Chadburn A, Christos P, et al. Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies. Ann Oncol 2008; 19:1327.</a></li><li><a class="nounderline abstract_t">Chen RW, Li H, Bernstein SH, et al. RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. Br J Haematol 2017; 176:759.</a></li><li><a class="nounderline abstract_t">Kamdar M, Li H, Chen RW, et al. Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma. Blood Adv 2019; 3:3132.</a></li><li><a class="nounderline abstract_t">Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 2013; 381:1203.</a></li><li><a class="nounderline abstract_t">Flinn IW, van der Jagt R, Kahl B, et al. First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study. J Clin Oncol 2019; 37:984.</a></li><li><a class="nounderline abstract_t">Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 2014; 123:2944.</a></li><li><a class="nounderline abstract_t">Hermine O, Hoster E, Walewski J, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet 2016; 388:565.</a></li><li><a class="nounderline abstract_t">Hermine O, Jiang L, Walewski J, et al. High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network. J Clin Oncol 2023; 41:479.</a></li><li><a class="nounderline abstract_t">Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005; 105:2677.</a></li><li><a class="nounderline abstract_t">Zoellner AK, Unterhalt M, Stilgenbauer S, et al. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol 2021; 8:e648.</a></li><li><a class="nounderline abstract_t">Abrahamsson A, Albertsson-Lindblad A, Brown PN, et al. Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study. Blood 2014; 124:1288.</a></li><li><a class="nounderline abstract_t">Gerson JN, Handorf E, Villa D, et al. Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era. J Clin Oncol 2019; 37:471.</a></li><li><a class="nounderline abstract_t">Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma. N Engl J Med 2017; 377:1250.</a></li><li><a class="nounderline abstract_t">Klener P, Salek D, Pytlik R, et al. Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation. Am J Hematol 2019; 94:E50.</a></li><li><a class="nounderline abstract_t">Ladetto M, Cortelazzo S, Ferrero S, et al. Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial. Lancet Haematol 2021; 8:e34.</a></li><li><a class="nounderline abstract_t">Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012; 367:520.</a></li><li><a class="nounderline abstract_t">Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. J Clin Oncol 2020; 38:248.</a></li><li><a class="nounderline abstract_t">Martin P, Cohen JB, Wang M, et al. Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts. J Clin Oncol 2023; 41:541.</a></li><li><a class="nounderline abstract_t">Rummel MJ, Knauf W, Goerner M, et al. Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial). (abstract 7503). J Clin Oncol 2016; 34.</a></li><li><a class="nounderline abstract_t">Kumar A, Ying Z, Alperovich A, et al. Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma. Haematologica 2019; 104:e163.</a></li><li><a class="nounderline abstract_t">Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009; 27:1209.</a></li><li><a class="nounderline abstract_t">Abrisqueta P, Scott DW, Slack GW, et al. Observation as the initial management strategy in patients with mantle cell lymphoma. Ann Oncol 2017; 28:2489.</a></li><li><a class="nounderline abstract_t">Cohen JB, Han X, Jemal A, et al. Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma. Cancer 2016; 122:2356.</a></li><li><a class="nounderline abstract_t">Leitch HA, Gascoyne RD, Chhanabhai M, et al. Limited-stage mantle-cell lymphoma. Ann Oncol 2003; 14:1555.</a></li><li><a class="nounderline abstract_t">Aukema SM, Hoster E, Rosenwald A, et al. Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network. Blood 2018; 131:417.</a></li><li><a class="nounderline abstract_t">Greenwell IB, Staton AD, Lee MJ, et al. Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. Cancer 2018; 124:2306.</a></li><li><a class="nounderline abstract_t">Clot G, Jares P, Giné E, et al. A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome. Blood 2018; 132:413.</a></li><li><a class="nounderline abstract_t">Sarkozy C, Terré C, Jardin F, et al. Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index. Genes Chromosomes Cancer 2014; 53:106.</a></li><li><a class="nounderline abstract_t">Beà S, Valdés-Mas R, Navarro A, et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci U S A 2013; 110:18250.</a></li><li><a class="nounderline abstract_t">Halldórsdóttir AM, Lundin A, Murray F, et al. Impact of TP53 mutation and 17p deletion in mantle cell lymphoma. Leukemia 2011; 25:1904.</a></li><li><a class="nounderline abstract_t">Greiner TC, Dasgupta C, Ho VV, et al. Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. Proc Natl Acad Sci U S A 2006; 103:2352.</a></li><li><a class="nounderline abstract_t">Lin RJ, Ho C, Hilden PD, et al. Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations. Br J Haematol 2019; 184:1006.</a></li><li><a class="nounderline abstract_t">Robinson SP, Boumendil A, Finel H, et al. Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party. Bone Marrow Transplant 2018; 53:617.</a></li><li><a class="nounderline abstract_t">Mussetti A, Kumar A, Dahi PB, et al. Lifting the mantle: Unveiling new treatment approaches in relapsed or refractory mantle cell lymphoma. Blood Rev 2015; 29:143.</a></li><li><a class="nounderline abstract_t">Merryman RW, Edwin N, Redd R, et al. Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. Blood Adv 2020; 4:858.</a></li><li><a class="nounderline abstract_t">Armand P, Redd R, Bsat J, et al. A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma. Br J Haematol 2016; 173:89.</a></li><li><a class="nounderline abstract_t">Tessoulin B, Chiron D, Thieblemont C, et al. Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: results from the LyMA prospective trial. Bone Marrow Transplant 2021; 56:1700.</a></li><li><a class="nounderline abstract_t">Delarue R, Haioun C, Ribrag V, et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. Blood 2013; 121:48.</a></li><li><a class="nounderline abstract_t">Geisler CH, Kolstad A, Laurell A, et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008; 112:2687.</a></li><li><a class="nounderline abstract_t">Eskelund CW, Kolstad A, Jerkeman M, et al. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol 2016; 175:410.</a></li><li><a class="nounderline abstract_t">Robak T, Jin J, Pylypenko H, et al. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet Oncol 2018; 19:1449.</a></li><li><a class="nounderline abstract_t">Robak T, Huang H, Jin J, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med 2015; 372:944.</a></li><li><a class="nounderline abstract_t">Ruan J, Martin P, Shah B, et al. Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma. N Engl J Med 2015; 373:1835.</a></li><li><a class="nounderline abstract_t">Albertsson-Lindblad A, Kolstad A, Laurell A, et al. Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma. Blood 2016; 128:1814.</a></li><li><a class="nounderline abstract_t">Gressin R, Daguindau N, Tempescul A, et al. A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma. Haematologica 2019; 104:138.</a></li><li><a class="nounderline abstract_t">Kolstad A, Laurell A, Jerkeman M, et al. Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. Blood 2014; 123:2953.</a></li><li><a class="nounderline abstract_t">Fenske TS, Zhang MJ, Carreras J, et al. Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. J Clin Oncol 2014; 32:273.</a></li></ol></div><div id="topicVersionRevision">Topic 4719 Version 59.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25113753" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32191807" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35653592" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35732829" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22425896" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Non-nodal type of mantle cell lymphoma is a specific biological and clinical subgroup of the disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28984300" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17962512" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20528872" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24687837" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22640180" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20032504" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17470738" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17943799" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21873544" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34781267" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : NCCN Guidelines®Insights: B-Cell Lymphomas, Version 5.2021.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34413469" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32885149" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : EHA Endorsement of ESMO Clinical Practice Guidelines for Newly Diagnosed and Relapsed Mantle Cell Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28881919" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28819011" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22234679" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18349031" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Intensive treatment strategies may not provide superior outcomes in mantle cell lymphoma: overall survival exceeding 7 years with standard therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27992063" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31648328" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23433739" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30811293" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24591201" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27313086" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36469833" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15591112" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34450102" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24859361" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30615550" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28953447" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30474171" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33357480" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22873532" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Treatment of older patients with mantle-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31804876" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35763708" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Treatment Outcomes and Roles of Transplantation and Maintenance Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma: Results From Large Real-World Cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial). (abstract 7503)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30930338" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Clinical presentation determines selection of patients for initial observation in mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19188674" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Outcome of deferred initial therapy in mantle-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28961827" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Observation as the initial management strategy in patients with mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27153197" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Deferred therapy is associated with improved overall survival in patients with newly diagnosed mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14504058" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Limited-stage mantle-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29196411" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29579328" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29769262" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24249260" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24145436" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Landscape of somatic mutations and clonal evolution in mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21720382" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Impact of TP53 mutation and 17p deletion in mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16461462" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30537212" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29335632" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25468719" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Lifting the mantle: Unveiling new treatment approaches in relapsed or refractory mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32126141" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26729345" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33658645" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: results from the LyMA prospective trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22718839" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18625886" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27378674" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30348538" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25738670" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26535512" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27354719" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30171024" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24652994" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24344210" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
